Iptacopan in IgA Nephropathy - Final 24-Month Data.

Area of Science:

• Nephrology
• Immunology
• Pharmacology

Background:

• Alternative complement pathway overactivation is implicated in IgA nephropathy (IgAN) pathogenesis and glomerular inflammation.
• Iptacopan, an oral complement factor B inhibitor, targets this pathway.
• Previous interim analysis showed iptacopan reduced proteinuria in IgAN patients.

Purpose of the Study:

• To evaluate the efficacy and safety of iptacopan in adults with IgA nephropathy.
• To assess the effect of iptacopan on the rate of kidney function decline over 24 months.
• To determine the impact of iptacopan on kidney failure events.

Main Methods:

• Phase 3, randomized, double-blind, placebo-controlled trial involving 477 adults with IgAN.
• Patients received oral iptacopan (200 mg) or placebo twice daily.
• Primary endpoint: annualized total eGFR slope over 24 months. Secondary endpoint: composite kidney-failure event rate.

Main Results:

• Iptacopan demonstrated a significantly slower annualized eGFR slope (-3.10 ml/min/1.73 m² per year) versus placebo (-6.12 ml/min/1.73 m² per year).
• The composite kidney-failure event rate was lower in the iptacopan group (21.4%) compared to placebo (33.5%).
• Adverse event rates were similar; serious infections were more frequent with iptacopan (6.7%) vs. placebo (2.1%).

Conclusions:

• Iptacopan therapy resulted in a significantly slower decline in kidney function compared to placebo in patients with IgAN.
• Iptacopan represents a potential therapeutic option for slowing IgAN progression.
• The study met its primary and secondary endpoints, supporting iptacopan's efficacy.